BioNTech Results Presentation Deck

Key Highlights for Q2 2022 23 Total Revenues ¹ €3.2 bn Diluted EPS A €6.45 Operating Result Ⓡ €2.2 bn Cash and Trade Receivables €9.3 bn + €10.4 bn 1 BioNTech's profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report on Form 20-F for the year ended December 31, 2021 as well as the Quarterly Report as of and for the three and six months ended June 30, 2022, filed as an exhibit to BioNTech's Current Report on Form 6-K filed on August 8, 2022. Any changes in the estimated share of the collaboration partner's gross profit will be recognized prospectively. BIONTECH

View entire presentation